BIND-014 is a targeted polymeric nanoparticle, and is an investigational therapeutic drug in phase 2 clinical trials for various cancers, eg. metastatic prostate cancer
BIND-014 is an Accurin nanomedicine produced by Bind Therapeutics Inc. BIND-014 targets prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells and the blood vessels of many types of solid tumors, and contains docetaxel as the cytotoxic agent.
Positive results in non-small cell lung cancer were presented in late 2014.
^ a b c d BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium
^ A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2)
^ A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
This medical treatment–related article is a stub. You can help Wikipedia by expanding it.